Journal Publishers to Police Themselves

The cost of commercial scientific, technical, and medical journals has risen faster than inflation as publishers' profits soar, according to a September report by the British Office of Fair Trading.1 Yet, despite the report's conclusion that the profits have risen at the expense of education and research institutions, the British OFT, a consumer-protection agency that aims to ensure businesses operate fairly, concluded that free-market forces may eventually correct the journal market imbalance

Written byDavid Bradley
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The cost of commercial scientific, technical, and medical journals has risen faster than inflation as publishers' profits soar, according to a September report by the British Office of Fair Trading.1 Yet, despite the report's conclusion that the profits have risen at the expense of education and research institutions, the British OFT, a consumer-protection agency that aims to ensure businesses operate fairly, concluded that free-market forces may eventually correct the journal market imbalance. "The market, which operates worldwide, has a number of features that suggest that competition may not be working effectively," says John Vickers, OFT director general, in a press statement. "However, market forces harnessing new technology may change this without the need for intervention."

The OFT report says that science, technology, and medical (STM) publishing showed 10% to 15% greater profitability over other commercial journal publishing with price increases above inflation, despite the introduction of electronic-delivery methods that should ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies